| Year |
Citation |
Score |
| 2019 |
Weisz L, Zalcenstein A, Stambolsky P, Cohen Y, Goldfinger N, Oren M, Rotter V. Retraction: Transactivation of the Gene Contributes to Mutant p53 Gain of Function. Cancer Research. 79: 2085. PMID 30987981 DOI: 10.1158/0008-5472.Can-19-0560 |
0.575 |
|
| 2012 |
Kalo E, Kogan-Sakin I, Solomon H, Bar-Nathan E, Shay M, Shetzer Y, Dekel E, Goldfinger N, Buganim Y, Stambolsky P, Goldstein I, Madar S, Rotter V. Mutant p53R273H attenuates the expression of phase 2 detoxifying enzymes and promotes the survival of cells with high levels of reactive oxygen species. Journal of Cell Science. 125: 5578-86. PMID 22899716 DOI: 10.1242/Jcs.106815 |
0.778 |
|
| 2011 |
Dell'Orso S, Fontemaggi G, Stambolsky P, Goeman F, Voellenkle C, Levrero M, Strano S, Rotter V, Oren M, Blandino G. ChIP-on-chip analysis of in vivo mutant p53 binding to selected gene promoters. Omics : a Journal of Integrative Biology. 15: 305-12. PMID 21332394 DOI: 10.1089/Omi.2010.0084 |
0.736 |
|
| 2011 |
Madar S, Stambolsky P, Rotter V. Unleash the wild type: restoration of p53 suppressive activity in skin cancer. Cell Cycle (Georgetown, Tex.). 10: 736-7. PMID 21311232 DOI: 10.4161/Cc.10.5.14928 |
0.625 |
|
| 2011 |
Kogan-Sakin I, Tabach Y, Buganim Y, Molchadsky A, Solomon H, Madar S, Kamer I, Stambolsky P, Shelly A, Goldfinger N, Valsesia-Wittmann S, Puisieux A, Zundelevich A, Gal-Yam EN, Avivi C, et al. Mutant p53(R175H) upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells. Cell Death and Differentiation. 18: 271-81. PMID 20689556 DOI: 10.1038/Cdd.2010.94 |
0.801 |
|
| 2010 |
Stambolsky P, Tabach Y, Fontemaggi G, Weisz L, Maor-Aloni R, Siegfried Z, Sigfried Z, Shiff I, Kogan I, Shay M, Kalo E, Blandino G, Simon I, Oren M, Rotter V. Modulation of the vitamin D3 response by cancer-associated mutant p53. Cancer Cell. 17: 273-85. PMID 20227041 DOI: 10.1016/J.Ccr.2009.11.025 |
0.76 |
|
| 2010 |
Stambolsky P, Tabach Y, Fontemaggi G, Weisz L, Maor-Aloni R, Siegfried Z, Shiff I, Kogan I, Shay M, Kalo E, Blandino G, Simon I, Oren M, Rotter V. Modulation of the Vitamin D3 Response by Cancer-Associated Mutant p53 (DOI:10.1016/j.ccr.2009.11.025) Cancer Cell. 17: 523. DOI: 10.1016/J.Ccr.2010.04.017 |
0.748 |
|
| 2009 |
Zemach A, Paul LK, Stambolsky P, Efroni I, Rotter V, Grafi G. The C-terminal domain of the Arabidopsis AtMBD7 protein confers strong chromatin binding activity. Experimental Cell Research. 315: 3554-62. PMID 19647732 DOI: 10.1016/J.Yexcr.2009.07.022 |
0.519 |
|
| 2007 |
Kalo E, Buganim Y, Shapira KE, Besserglick H, Goldfinger N, Weisz L, Stambolsky P, Henis YI, Rotter V. Mutant p53 attenuates the SMAD-dependent transforming growth factor beta1 (TGF-beta1) signaling pathway by repressing the expression of TGF-beta receptor type II. Molecular and Cellular Biology. 27: 8228-42. PMID 17875924 DOI: 10.1128/Mcb.00374-07 |
0.738 |
|
| 2006 |
Buganim Y, Kalo E, Brosh R, Besserglick H, Nachmany I, Rais Y, Stambolsky P, Tang X, Milyavsky M, Shats I, Kalis M, Goldfinger N, Rotter V. Mutant p53 protects cells from 12-O-tetradecanoylphorbol-13-acetate-induced death by attenuating activating transcription factor 3 induction. Cancer Research. 66: 10750-9. PMID 17108111 DOI: 10.1158/0008-5472.Can-06-0916 |
0.773 |
|
| 2006 |
Stambolsky P, Weisz L, Shats I, Klein Y, Goldfinger N, Oren M, Rotter V. Regulation of AIF expression by p53. Cell Death and Differentiation. 13: 2140-9. PMID 16729031 DOI: 10.1038/Sj.Cdd.4401965 |
0.701 |
|
| 2006 |
Zalcenstein A, Weisz L, Stambolsky P, Bar J, Rotter V, Oren M. Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53. Oncogene. 25: 359-69. PMID 16170349 DOI: 10.1038/Sj.Onc.1209061 |
0.71 |
|
| 2004 |
Weisz L, Zalcenstein A, Stambolsky P, Cohen Y, Goldfinger N, Oren M, Rotter V. Transactivation of the EGR1 gene contributes to mutant p53 gain of function. Cancer Research. 64: 8318-27. PMID 15548700 DOI: 10.1158/0008-5472.Can-04-1145 |
0.764 |
|
| 2004 |
Shats I, Milyavsky M, Tang X, Stambolsky P, Erez N, Brosh R, Kogan I, Braunstein I, Tzukerman M, Ginsberg D, Rotter V. p53-dependent down-regulation of telomerase is mediated by p21waf1. The Journal of Biological Chemistry. 279: 50976-85. PMID 15371422 DOI: 10.1074/Jbc.M402502200 |
0.776 |
|
| 2004 |
Erez N, Stambolsky P, Shats I, Milyavsky M, Kachko T, Rotter V. Hypoxia-dependent regulation of PHD1: cloning and characterization of the human PHD1/EGLN2 gene promoter. Febs Letters. 567: 311-5. PMID 15178343 DOI: 10.1016/J.Febslet.2004.05.003 |
0.551 |
|
| 2003 |
Zalcenstein A, Stambolsky P, Weisz L, Müller M, Wallach D, Goncharov TM, Krammer PH, Rotter V, Oren M. Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants. Oncogene. 22: 5667-76. PMID 12944915 DOI: 10.1038/Sj.Onc.1206724 |
0.689 |
|
| 2001 |
Matas D, Sigal A, Stambolsky P, Milyavsky M, Weisz L, Schwartz D, Goldfinger N, Rotter V. Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis. The Embo Journal. 20: 4163-72. PMID 11483519 DOI: 10.1093/Emboj/20.15.4163 |
0.792 |
|
| 2001 |
Almog N, Milyavsky M, Stambolsky P, Falcovitz A, Goldfinger N, Rotter V. The role of the C' terminus of murine p53 in the p53/mdm-2 regulatory loop. Carcinogenesis. 22: 779-85. PMID 11323398 DOI: 10.1093/Carcin/22.5.779 |
0.695 |
|
| Show low-probability matches. |